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Background: In patients withMarfan syndrome, the complications of aortic degeneration, including dissection, aneurysm,
and rupture represent the main cause of mortality. Although contemporary management of ascending aortic disease
requires open surgical reconstruction, endovascular repair is now available for management of descending thoracic and
abdominal aortic pathology (ie, thoracic endovascular aortic repair [TEVAR], endovascular aneurysm repair [EVAR]).
The short- and long-term benefit of endovascular repair in Marfan patients remains largely unproven. We examine our
outcomes after EVAR in this patient population.
Methods: All patients with a diagnosis of Marfan syndrome who were treated with TEVAR/EVAR were evaluated in a
retrospective review. Perioperative, procedure-specific and patient covariate data were aggregated. Primary endpoints
were overall mortality and procedural success as divided into three categories: (1) successful therapy, (2) primary failure,
or (3) secondary failure.
Results: Between 2000 and June 2010, 16 patients were identified as having undergone 19 TEVAR/EVAR procedures.
These included three emergent operations (two for acute dissection/malperfusion and one for anastomotic disruption
early after open repair). All 16 patients had previously undergone at least one (range, 1-5) open operation of the
ascending aorta or arch at a time interval from 33 years to 1 week prior to the index endovascular repair. During a median
follow-up of 9.3 months (range, 0-46 months), there were four deaths (25%). Six patients (38%) had successful
endovascular interventions. Despite early success, there was one death in this group at 1 month postintervention. Seven
patients (44%) experienced primary treatment failure with five undergoing open conversion and one undergoing left
subclavian coil embolization (the seventh was lost to follow-up and presented 4 months later in cardiac arrest and expired
without repair). There were three deaths in the primary treatment failure group. Two patients experienced secondary
treatment failure. One underwent the index TEVAR for acute dissection with malperfusion and required a subsequent
TEVAR for more distal aortic pathology. He is stable without disease progression. The other patient underwent open
conversion after a second EVAR with four-vessel “chimney” stent grafts and is stable with his entire native aorta having
been replaced.
Conclusions: Aortic disease associated with Marfan syndrome is a complex clinical problem and many patients require
remedial procedures. Endovascular therapy can provide a useful adjunct or bridge to open surgical treatment in selected
patients. However, failure of endovascular therapy is common, and its use should be judicious with close follow-up to
avoid delay if open surgical repair is required. (J Vasc Surg 2012;55:1234-41.)
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eMarfan syndrome is a connective tissue disease in which
the vascular manifestations of the syndrome, specifically
dissection/aneurysm and subsequent rupture, are the larg-
est source of morbidity and mortality for affected individ-
uals. Since the late 1960s, patients with Marfan syndrome
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1234ave undergone aortic root and valve replacement as de-
cribed by Bentall1 to treat ascending aortic aneurysms of 5
m or greater. Aortic surgery for individuals with Marfan
yndrome brought a much improved life expectancy and
uickly became the standard of care for treating these
atients.2
Despite operative success and improved survival follow-
ng ascending aortic repair, it is well known that patients
ith Marfan syndrome continue to experience aortic de-
eneration throughout their lives, leading to remedial aor-
ic interventions. In a study, including 675Marfan patients
ndergoing aortic root replacement, Gott et al2 reported
hat 14% of patients had a history of previous aortic surgery.
hose patients who had undergone a previous aortic oper-
tion had a 60-day mortality that was fivefold higher than
hose who had not.3 Gott’s study also showed that subse-
uent dissection or rupture of the residual aorta was the
eading cause of late death (defined as greater than 30
ays). Additionally, other authors have reported that reop-
ration rates for Marfan patients is as high as 27%,4 with a
ortality rate of reoperation up to 31%.5
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Volume 55, Number 5 Waterman et al 1235As Marfan patients who have been treated with stan-
dard open operations advance in age and experience pro-
gression of their aortic pathology, options for safe open
interventions diminish. The advent of endovascular thera-
pies has provided an attractive alternative for patients who
are high risk for open operation. Selected use of endovas-
cular therapies in theMarfan population has been described
in several case reports and series.6-12 The short- and long-
term benefits are unproven and this practice remains con-
troversial. In the 2008 Expert Consensus Document on the
Treatment of Descending Thoracic Aortic Disease Using En-
dovascular Stent Grafts, The Society of Thoracic Surgeons
Endovascular Surgery Task Force stated that “stent graft-
ing in patients with Marfan syndrome or any other known
connective tissue disorder is not recommended [as] there is
limited information regarding the impact of persistent ra-
dial forces of a stent graft in the abnormal and weak
aorta.”13 Despite this, some of these studies have demon-
strated beneficial results of applying endovascular technol-
ogy to a select subset of theMarfan population. This subset
includes those patients with few safe open alternatives,
complicated surgical histories, those at increased risk for
perioperative complications, and patients requiring salvage
therapy following complicated open interventions.
The University of Florida has a long history of treating
Marfan patients, and as our practice has evolved to include
more endovascular therapies, these techniques have been
applied to our Marfan patients in a highly selective manner.
This study was designed to examine our outcomes after
endovascular repair of the descending thoracic and abdom-
inal aorta in patients with Marfan syndrome.
METHODS
Patient population. In the University of Florida aor-
tic database, patients are prospectively entered at the time
of surgery by the operating surgeon. All complications and
subsequent surgeries are entered as they occur. This data-
base was queried in a retrospective manner for all patients
with a clinical diagnosis of Marfan syndrome who have
undergone endovascular aortic repair (thoracic endovascu-
lar aortic repair [TEVAR] or endovascular aneurysm repair
[EVAR]) during the period of January 2000-June 2010.
The diagnosis of Marfan syndrome for this study was based
on patient report; physical examination findings and clinical
history were felt to support the diagnosis. None in this
series had genetic testing showing a fibrillin-1 gene muta-
tion done at our institution. A retrospective chart review
of the inpatient and outpatient medical record was per-
formed examining past medical and surgical history,
operative characteristics, follow-up imaging, any interven-
tions performed subsequent to stenting, and postoperative
morbidity and mortality. The social security death index
(SSDI) was reviewed to ensure all mortalities were captured
by trained data abstractors.
All patients underwent a thorough preoperative review
in a multidisciplinary group of vascular and cardiothoracic
surgeons. Patients who were deemed poor candidates for
open surgical intervention or a high risk for perioperative oomplications based on medical or anatomic risk factors
ere considered for endovascular therapy.
Preoperative device planning was carried out using a
hree-dimensional workstation (Aquarius 3D Workstation;
eraRecon Inc, Foster City, Calif). All procedures were
arried out in a hybrid endovascular suite by an experienced
eam of vascular and cardiothoracic surgeons. All postop-
rative imaging was reviewed in a similar multidisciplinary
ormat and treatment plans were jointly formulated.
Results are reported as stipulated by Fillinger et al in the
ociety for Vascular Surgery document Reporting stan-
ards for thoracic endovascular aortic repair (TEVAR).14
pproval for this study was obtained from the Institutional
eview Board at the University of Florida.
Devices. Prior to July 2008, thoracic repairs were per-
ormed exclusively with Gore TAG stent grafts (W. L. Gore
nd Associates, Flagstaff, Ariz) (n  9). After July 2008,
ook Zenith TX2 grafts (Cook Medical, Inc. Blooming-
on, Ind) were also used (n 11). Two patients had EVAR
n conjunction with TEVAR and were repaired using the
ook TX2 and Cook Zenith devices. These devices are not
ood and Drug Administration (FDA) approved for use in
issections, and thus the treatments described in this man-
script are off label by definition.
Analysis and statistics. Procedural success was cate-
orized into three groups: (1) successful therapy, (2) pri-
ary failure, or (3) secondary failure. Successful therapy
as defined as clinically and radiographically successful
reatment of the target pathology with no follow-up inter-
entions required during follow-up. Primary failure was
efined as a type I endoleak, persistent false lumen flow in
he stented aorta leading to aneurysmal degeneration,
nd/or need for subsequent operative interventions (open
r endovascular) to address the original presenting aortic
athology. Secondary failure was defined as initially suc-
essful treatment of the target aortic pathology with aortic
egeneration proximal or distal to the stent graft requiring
urther intervention that was unrelated to the original
resentation or endovascular procedure performed.
Limited statistical analysis was required, but was per-
ormed with Microsoft Excel (simple calculations).
ESULTS
atient population
Between January 2000 and June 2010, 16 Marfan
atients were identified as having undergone 19 aortic stent
raft procedures. Patient demographics and comorbidities
re demonstrated in Table I. The median patient age was
9.6 years (range 26 to 65 years) at the index endovascular
rocedure. Fourteen of 16 patients were ASA class IV or
V-E. Our median follow-up was 9.3 months (mean, 13.7
onths; range, 1-46 months).
All 16 patients had undergone previous open aortic
urgery; a total of 30 prior operations with an average of 1.9
range, 1-5) open cardiovascular procedures per patient
Table II). Seven patients had undergone two or more
perations. Timing of previous open operation ranged
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May 20121236 Waterman et alfrom 33 years to 1 week before stent grafting. Most of the
30 prior operations were a combination of procedures
spanning the aortic valve to the bifurcation, including
various combinations of 14 cardiac, 20 aortic root or as-
cending aorta, 10 arch, five descending thoracic aorta, one
thoracoabdominal aorta, and one aorto-bi-iliac bypass.
The indication for intervention was chronic dissection
with aneurysmal degeneration in 11 patients, acute dissec-
tion with associated malperfusion in two patients, pseudo-
aneurysm in two patients, and acute postoperative anasto-
motic disruption in one patient 10 days following an open
ascending/arch/descending repair.
Endovascular procedural characteristics
Eight primary procedures were elective, four were ur-
gent, and three were emergent. Seven procedures were
performed under regional anesthesia and the remaining
operations were performed using general anesthesia.
Adjunctive endovascular procedures were performed in
eight of the index operations. Two patients underwent
antegrade stent graft placement in conjunction with open
aortic intervention. Three patients underwent staged re-
pairs, including two arch debranchings (3 weeks and 3
months preoperatively) and one emergent ascending/
arch/elephant trunk 6 days prior to TEVAR. Intraopera-
tive adjunctive procedures included subclavian artery em-
bolization (one), vertebral artery stent (one), renal artery
stent (one), celiac (one), and SMA stent (one). One patient
underwent a four-vessel “chimney” (celiac, SMA, right and
left renal artery stent grafts) repair with TEVAR. The
proximal zone of attachment was zone 0 in four patients,
zone 2 in 10 patients, and zone 3 in three patients.
There were no intraoperative open conversions at the
time of endovascular repair. Operative data for the index
endovascular procedures are as follows: median operative
Table I. Patient characteristics
Patients (n) 16
Median age, years 40 (range, 26-65)
M:F ratio 13:3
Prior aortic surgery (n) 16
Average number of procedures per patient 1.9 (range, 1-5)
ASA class (n)
III 2
IV or IV-E 14
Comorbidities (n)
Hypertension 8
Hyperlipidemia 3
Atrial fibrillation 3
CAD/MI 2
CHF 2
CVA 2
Pulmonary hypertension 1
COPD 1
Cardiomyopathy 1
ASA, American Society for Anesthesiologists;CAD, coronary artery disease;
CHF, congestive heart failure; COPD, chronic obstructive pulmonary dis-
ease; CVA, cerebrovascular accident; MI, myocardial infarction.time was 116 minutes (range, 75-509 minutes). Median muoroscopy time was 31 minutes (range, 0-171 minutes),
edian contrast usage was 172mL (range, 0-290mL), and
edian length of stay following the primary TEVAR/
VAR was 7 days (range, 2-77).
herapeutic success
Table II demonstrates detailed patient history and the
uccess of the operation. One patient had what appeared to
e a successful therapy intraoperatively, but was lost to
ollow-up on discharge and was not included in these
roups because of lack of follow-up.
Successful therapy. Six patients (38%) had successful
herapy and required no subsequent interventions over a
edian follow-up of 6.8months (average, 12.7 months;
ange, 1-33).
Two patients in this group are notable due to a partic-
larly complex pre-TEVAR history. One developed an
nastomotic pseudoaneurysm 12 days after his fifth open
ortic surgery. He underwent an urgent TEVAR on post-
perative day (POD) 13 from that open intervention and
o further intervention has been required over 32 months
f follow-up. The other notable patient had a history of an
mergent valve-sparing aortic root repair with arch deb-
anching and extra-anatomic bypasses for an acute dissec-
ion with lower extremity malperfusion. Two weeks later,
e underwent TEVAR and excision of his extra-anatomic
ypasses. He was stable without progression of disease at
is last follow-up, which was 3 months after repair.
There was one death in this group. The patient who
nderwent TEVAR for acute postoperative anastomotic
isruption had her aorta successfully sealed; however, had a
rolonged and complicated ICU course and died at post-
perative day 30 with multiorgan failure.
Primary treatment failure. Seven patients (44%) ex-
erienced primary treatment failure. One had persistent
alse lumen flow that eventually led to aneurysmal degen-
ration of the descending thoracic aorta, and one had a
etrograde dissection into the transverse aorta. Three were
ound to have a type I endoleak. One patient had what
ppeared to be successful intraoperative treatment, but
ent on to rupture. Five of these patients, underwent open
onversion and aortic reconstruction after unsuccessful en-
ovascular therapy, and their course will each be discussed
urther below. One had a type II endoleak from the L
ubclavian leading to continued aneurysmal degeneration.
e underwent successful coil embolization successfully
esolving the endoleak.
One patient had an apparent successful therapy intra-
peratively, but experienced a hypertensive emergency
eading to aortic rupture on postoperative day two. He
nderwent successful emergent open conversion, but had
ultiple complications, a difficult postoperative course and
ent on to die 3 months later in a long-term treatment
acility.
The patient with persistent false lumen flow and aneu-
ysmal degeneration underwent an explantation of the en-
ograft and open type II thoracoabdominal repair with no
ajor complications.
r
t
p
f
f
P
t
i
a
s
; SSD
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 5 Waterman et al 1237The patient with retrograde dissection into the trans-
verse aorta underwent replacement of his ascending/arch
and descending aorta with graft removal and recovered
uneventfully.
Of the three patients with a type I endoleak, one patient
was lost to follow-up despite extensive attempts to schedule
repair. He eventually presented to the emergency depart-
ment 4 months later in cardiac arrest and expired without
repair. Unfortunately, he did not undergo post-mortem
examination, and the cause of his death is unknown. One
Table II. Operative indications, prior surgery, operative/m
Pt. No. Indication P
1 Aneurysm (1) Asc/St.
2 Intraoperative anastomotic
disruption
(1) Type I d
(2) AVR
(3) Asc/Arc
(4) Mediasti
tampona
3 Pseudoaneurysm (1) Asc/St.
(2) Emergen
false ane
(3) Ao-bi-ili
(4) Type II
4 Aneurysm (1) Emergen
5 Aneurysm (1) Emergen
A dissect
6 Pseudoaneurysm (proximal
dTAA anastomosis)
(1) Asc/Val
(2) dTAA re
(3) Asc/Arc
(4) Asc/Arc
(5) Distal dT
7 Aneurysm (1) Ascendin
(2) Asc/Arc
8 Aneurysm (1) Asc/Arc
9 Acute dissection with
malperfusion
Emergent A
with Inno
carotid by
10 Aneurysm (1) Emergen
(2) Asc/Arc
11 Aneurysm (1) Asc/Val
12 Aneurysm (1) Asc/Val
13 Acute dissection with
malperfusion
(1) Asc/Val
(2) MV repa
14 Aneurysm (1) Asc/Arc
trunk
15 Aneurysm (1) AVR (St
16 Aneurysm (1) Coarctat
(2) Asc/Val
Asc, Ascending;AUI, aorto-uni-iliac;AVR, aortic valve repair/replacement;
FL, false lumen; MV, mitral valve; POD, postoperative day; SC, subclavian
thoracoabdominal aortic aneurysm.patient underwent graft explantation and descending tho- lacic aortic replacement and has had no further interven-
ions to date. The third patient with a type I endoleak was
articularly complicated and underwent the index TEVAR
or a symptomatic pseudoaneurysm of the distal arch after
our prior open aortic reconstructions. He was noted on
OD 1 to have a type I endoleak and underwent explanta-
ion of the graft and his fifth open operation of his ascend-
ng/arch/descending aorta. He recovered from that oper-
tion, but unfortunately went on to develop another
ymptomatic pseudoaneurysmof the paravisceral aorta 2 years
ality outcome, and subsequent interventions
ortic surgery
Aortic device/adjuvant
procedures
valve conduit TAG
ion repair
sc replacement
-exploration for
TAG (antegrade via ascending
arch conduit)
“Salvage therapy”
valve conduit
ection/repair ascending
/CABG
ass
coabdominal
(1) TAG w R vertebral stenting
(2) Aorto-SMA/R renal/celiac
bypass, TAG/TX2 “salvage
therapy” (T2years)
/Arch/Prox Desc TAG
R/Asc (2001) for type TAG
duit
lacement
udoaneurysm repair
epair
TAG and L SC coil
embolization
lacement
ranching
TAG
e conduit TX-2
ch (Florida Sleeve)
e and L common
TX-2 and excision extra-
anatomic bypasses
nding
hant trunk
TX-2
duit TX-2
duit TX-2
duit (1) TX-2 Proform (2) TX-2
rida Sleeve, elephant TX-2 Proform w SMA/celiac
stenting
) (1) TAG
(2) TX2 distal extension w
four-vessel chimney (AUI)
pair
duit
TX-2 (antegrade) with
ascending replacement and
arch debranching
, coronary artery bypass graft; dTAA, descending thoracic aortic aneurysm;
I, Social Security Death Index; SMA, superior mesenteric artery; TAAA,ort
rior a
Jude
issect
h/De
nal re
de
Jude
t res
urysm
ac byp
thora
t Asc
t AV
ion
ve con
pair
h rep
h pse
AA r
g rep
h deb
h valv
sc/Ar
minat
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t asce
h elep
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ve con
ve con
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CABGater. He was treated with a hybrid visceral debranching/
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operation.
Secondary treatment failure. Two patients had sec-
ondary failure of their TEVAR, including one who was
treated for an acute dissection with associated lower ex-
tremity malperfusion. Both patients had initially successful
therapy with thrombosis of the false lumen and favorable
aortic remodeling at the site of the stent graft. However,
both had persistent false lumen flow in the downstream
aorta from distal aortic fenestrations with subsequent an-
eurysmal degeneration of the thoracoabdominal aorta.
They both underwent subsequent distal TEVAR/EVAR,
Table II. Continued.
Success of intervention
Unknown: no follow-up Unknow
Successful therapy None
Primary failure: graft excision, open repair (1) Attem
repla
(2) Viabo
pseud
Successful therapy None
Primary failure: graft excision, open repair Open de
explan
Successful therapy None
Primary failure: persistent FL flow with continued
aneurysmal degeneration
Open rep
Successful therapy None
Successful therapy None
Primary failure: type I endoleak. None
Primary failure: retrograde dissection into arch/
persistent FL flow
Asc/Arch
explan
Primary failure: hypertensive rupture on POD 2 Emergen
Secondary failure: Distal thoracic aorta with
persistent FL flow and aneurysmal
degeneration
Subseque
Successful therapy None
Secondary failure; persistent FL flow in distal
thoracic/abdominal aorta¡ aneurysmal
degeneration of paravisceral aorta
(1) Cinch
(2) Exten
(3) C-SC
(4) Thor
with
viscer
Primary failure: type II endoleak via L SC artery L SC coione with four-vessel “chimney” stent grafts. One of these patients is stable without progression of disease 9 months
fter his second procedure. The patient who underwent
our-vessel “chimney” required open conversion with stent
raft explantation due to a persistent type 1 endoleak and
neurysmal degeneration of the abdominal aorta.
ISCUSSION
Although many advances have been made in aortic
urgery since the first description of Marfan syndrome, the
ardiovascular complications of the disease continue to be
he major source of morbidity and mortality in this patient
equent procedures Outcome
Unknown- (not dead per
SSDI)
Death on POD 30
cinch¡ Asc/Arch/Desc
t w stent explantation
tenting left EIA
urysm
Death on POD 19 without
stent (1) and with stent (2)
Alive and stable
ing repair with stent graft Alive without stent
Alive and stable
f type 2 TAAA Alive and stable
Alive and stable
Alive and stable
Death: Lost to follow-up.
Presented in cardiac arrest
with hypoxic brain death 4
months postop.
sc replacement with graft Alive without stent
n repair ruptured dTAA Death: 3 months postop of
respiratory complications
X-2 of distal TAA Alive and stable
Alive and stable
stent
ss
dominal aneurysm repair
explantation and multi-
pass
Alive without stents stable
olization Alive and stableSubs
n
pted
cemen
nd s
oane
scend
tation
air o
/De
tation
t ope
nt T
sion
bypa
acoab
stent
al by
l embopulation. Endovascular therapy has emerged as a viable
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Volume 55, Number 5 Waterman et al 1239alternative to open repair of thoracic aortic pathology, with
less perioperative mortality and morbidity. Each of the
major device manufacturers has begun trials investigating
the use of this technology for aortic dissection, exclusive of
those patients with known connective tissue disorders, with
some encouraging preliminary results. However, the use of
endovascular therapy for patients with Marfan syndrome is
still controversial and has been reported only in small series
and isolated case reports.6-12 To our knowledge, our anal-
ysis represents the largest series published to date.
In this series, TEVARwas performed in 15 patients and
EVAR in one patient. Successful therapy with the first
endovascular intervention was achieved in 38%. Unfortu-
nately, 44% of patients had primary failure of endovascular
stenting. The majority of these patients had subsequent
open operative therapy that was not precluded by the
endovascular procedure. It is bothersome that there was a
43% mortality in the primary failure group, but this is likely
an indication of the complexity of their presentation and
the difficulty of their subsequent open repair, rather than a
direct result of the endovascular intervention.
We examined patients by indication for surgery
(chronic dissection with aneurysmal degeneration [n 
11], acute dissection [n  2], pseudoaneurysm [n  1],
aneurysm [n  1], anastomotic disruption [n  1]). All
primary treatment failures fell into the chronic dissection
group, but this is not entirely surprising given that 11 of 16
patients had chronic dissection. Of note, there were three
patients with chronic disease who have required no further
interventions to date. Unfortunately, the small number of
patients in this analysis and their varied nature does not
allow for a subset analysis or specific recommendations
based on chronicity of the disease process.
Due to the complexity of the patients reported in our
series, this essentially represents an extended case series, but
it is worth comparing to the existing literature. Table III
summarizes our results in comparison with other published
data on endovascular therapies in Marfan syndrome. In all
of these studies, the patients were very complex in terms of
Table III. Summary of published data on endovascular th
No. Prior procedures
T
Yes
Waterman et al (2011) 16 1-5 6
Geisbausch et al11
(2008)
6 1-3 (n  4) 3
Marcheix et al12 (2008) 15 1 (n  11) 3
Baril et al10 (2006) 6 1 (n  4) 2
2 (n  2)
Botta et al7 (2006) 1 2 1
Dong et al16 (2005) 2 0 2
Ince et al9 (2005) 6 1 (n  5) 2
Fleck et al6 (2003) 1 4 1
Roux et al17 (2002) 1 2 1
Zaman et al18 (2002) 1 NA 1
NA, Not available; PTF, primary treatment failure; STF, secondary treatmenprior aortic procedures, and all were deemed to be at high tperative risk for open aortic surgery. Marcheix et al
howed a similarly high primary treatment failure rate to
ur study, with primary endoleak occurring in 33% of
atients, secondary endoleak occurring in another 33%, and
n additional two patients requiring subsequent interven-
ion for unrelated aortic pathology.12 There was a 60%
ortality in the primary endoleak group, and eight of 15
atients in this study required subsequent operative inter-
ention, mirroring the results in our series.
Limitations of our report include that it is a retrospective
eview of a small patient population with very complex aortic
natomy and short-term follow-up. Additionally, the diagno-
is of Marfan syndrome in our patients was based on patient
eport and clinical findings; no patient had a documented
brillin-1 gene mutation in our system. Despite the lack of
enetic testing in our series, the revised Ghent criteria pub-
ished in 2010 reported a 90% concordance between the old
nd revised Ghent nosology indicating the diagnosis by the
lder criteria was fairly accurate.15 Fifteen of our 16 patients
nderwent their initial endo-intervention prior to the pub-
ication of the revised criteria when clinical diagnosis was
till the standard.
This group of patients clearly represents a therapeutic
ilemma because open surgical procedures in the complex
roup of patients described in this study are fraught with
otential complications. Endovascular therapy is not a pana-
ea,with less thanhalf of the patients exhibiting a radiographic
esolution of the target aortic pathology.However, there does
eem to be a subset of Marfan patients who can benefit from
hese less invasive options, and this subset is yet to be clearly
efined.
It is our current practice to evaluate all Marfan patients in
multidisciplinary manner. Patients who are good risk, who
ave not had multiple aortic operations, are typically offered
pen repair, as this remains the gold standard therapy and has
roven long-term outcomes. We continue to offer endovas-
ular therapy only to those patients who we feel have poor or
o open options, or those we believe would not survive an
pen operation. It is imperative that Marfan patients be
for Marfan syndrome (adapted from Akin et al 2008)
al success
Subsequent
procedures Mortality
Follow-up
length (months)TF STF
7 2 8 4 13.7
2 1 2 0 31
0 2 8 3 25
1 3 4 0 29
– – 0 0 12
– – 0 0 12-16
4 – 2 1 12-74
– – 0 0 36
– – 0 0 NA
– – 0 0 12
re.erapy
echnic
P
1reated and followed closely at medical centers with sufficient
11
1
1
1
1
1
1
1
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May 20121240 Waterman et albreadth of experience in both open and endovascular aortic
surgery so that endovascular treatment failure can be quickly
recognized and further therapy can be offered.
CONCLUSIONS
Aortic disease associated with Marfan syndrome is a
complex clinical problem, however, some Marfan patients
may benefit from endovascular management. All patients
require close lifetime follow-up at a center specializing in
aortic surgery, as the rate of primary and secondary treat-
ment failure is high and many will require subsequent
interventions, including open conversion. Careful consid-
eration and collaboration between surgical specialties is
important prior to endovascular intervention to ensure that
an open operative intervention is not delayed, precluded, or
further complicated by the planned procedure.
AUTHOR CONTRIBUTIONS
Conception and design: AW, RF, AL, PH, TM, TB, TH,
AB
Analysis and interpretation: AW, AB
Data collection: AW, RF, AL, PH, TM, TB, AB
Writing the article: AW, RF, AB
Critical revision of the article: AW, RF, PH, TM, TB, AB
Final approval of the article: AW, RF, TH, AB
Statistical analysis: AW, AB
Obtained funding: Not applicable
Overall responsibility: AB
REFERENCES
1. Bentall H, De Bono A. A technique for complete replacement of the
ascending aorta. Thorax 1968;23:338-9.
2. Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman
MJ, et al. Life expectancy in the Marfan syndrome. Am J Cardiol
1995;75:157-60.
3. Gott VL, Greene PS, Alejo DE, CameronDE, Naftel DC,Miller DC, et
al. Replacement of the aortic root in patients withMarfan. NEngl JMed
1999;340:1307-13.
4. Mingke D, Dresler C, Pethig K, Heinemann M, Borst HG. Surgical
treatment of Marfan patients with aneurysms and dissection of the
proximal aorta. J Cardiovasc Surg (Torino) 1998;39:65-74. S
degeneration requiring further intervention.
I have the following questions for the authors:
(
(
(
(5. Akin I, Kische S, Rehders TC, Chatterjee T, Schneider H, Körber T, et
al. Current role of endovascular therapy in Marfan patients with previ-
ous aortic surgery. Vasc Health Risk Manag 2008;4:59-66.
6. Fleck TM, Hutschala D, Tschernich H, Rieder E, Czerny M, Wolner E,
et al. Stent graft placement of the thoracoabdominal aorta in a patient
with Marfan syndrome. J Thorac Cardiovasc Surg 2003;125:1541-3.
7. Botta L, Russo V, Grigioni F, Arpesella G, Rocchi G, Di Bartolomeo R,
et al. Unusual rapid evolution of type B aortic dissection in a Marfan
patient following heart transplantation: successful endovascular treat-
ment. Eur J Vasc Endovasc Surg 2006;32:358-60.
8. Beregi JP, Haulon S, Otal P, Thony F, Bartoli JM, Crochet D, et al.
Endovascular treatment of acute complications associated with aortic
dissection: midterm results from a multicenter study. J Endovasc Ther
2003;10:486-93.
9. Ince H, Rehders TC, Petzsch M, Kische S, Nienaber CA. Stent grafts in
patients with Marfan syndrome. J Endovasc Ther 2005;12:82-8.
0. Baril DT, Carroccio A, Palchik E, Ellozy SH, Jacobs TS, Teodorescu V,
et al. Endovascular treatment of complicated aortic aneurysms in pa-
tients with underlying arteriopathies. Ann Vasc Surg 2006;20:464-71.
1. Geisbüsch P, Kotelis D, von Tengg-Kobligk H, Hyhlik-Dürr A, Allen-
berg JR, Böckler D. Thoracic aortic endografting in patients with
connective tissue diseases. J Endovasc Ther 2008;15:144-9.
2. Marcheix B, Rousseau H, Bongard V, Heijmen RH, Nienaber CA,
Ehrlich M, et al. Stent grafting of dissected descending aorta in patients
with Marfan syndrome. J Am Coll Cardiol Intervent 2008;1:673-80.
3. Svensson LG, Kouchoukos NT, Miller DC, Bavaria JE, Coselli JS, Curi
MA, et al. Expert consensus document on the treatment of descending
thoracic aortic disease using endovascular stent grafts. Ann Thorac Surg
2008;85:S1-41.
4. Fillinger MF, Greenberg RK, McKinsey JF, Chaikof EL, Society for
Vascular Surgery Ad Hoc Committee on TEVAR Reporting Standards.
Reporting standards for thoracic endovascular aortic repair (TEVAR). J
Vasc Surg 2010;52:1022-33.
5. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J,
Devereux RB, et al. The revised Ghent nosology for the Marfan
syndrome. J Med Genet 2010;47:476-85.
6. Dong Xu S, Zhong Li Z, Huang FJ, Yang JF, Wang XY, Zhang ZG, et
al. Treating aortic dissection and penetrating aortic ulcer with stent
graft: thirty cases. Ann Thorac Surg 2005;80:864-8.
7. Roux D, Brouchet L, Rousseau H, Elghobary T, Glock Y, Fournial G.
Treatment of a fistula at the distal anastomosis after Bentall operation
with endoluminal covered stent. Ann Thorac Surg 2002;74:2189-90.
8. Zaman MJ, Carre V, Parvin S, Shepherd D, Radvan J. Endovascular
stent repair for a dissecting thoracoabdominal aneurysm is feasible in the
setting of a district general hospital: a multidisciplinary approach. Heart
2002;88:e4.ubmitted Aug 22, 2011; accepted Nov 14, 2011.DISCUSSION
Dr Eric D. Endean (Lexington, Ky). I would like to congrat-
ulate the group from the University of Florida for the courage of
presenting their results for this difficult problem. The patients
presented in this series clearly represent a group for which treat-
ment options are difficult at best. To re-emphasize, 14 of the 16
patients were ASA class IV or IV-E and all were deemed poor
candidates for open surgical intervention. Fifteen patients had
undergone between one and five previous open aortic opera-
tions, averaging almost two open aortic operations per patient.
Not unexpectedly, the results are sobering. Four patients died
within months of the endovascular procedure and the results in
50% were classified as “successful.” Six patients, or 38%, were
classified as primary treatment failures. All patients with treat-
ment failures required an open repair and half of them died.
Two patients were felt to have secondary failure, ie, successful
treatment of the target pathology, but proximal or distal aortic1) As mentioned in the manuscript, the diagnosis of Marfan
syndrome was based on clinical assessment and/or patient
report. One patient had his initial aortic procedure at age 76.
How confident are you that all of the patients in this series
actually had Marfan syndrome?
2) This report examines only patients undergoing endovascular
treatment for Marfan syndrome. Over the same time period,
do the authors have information regarding how many patients
were treated for Marfan syndrome with an open repair?
3) All patients were believed to be high risk for open repair, yet
almost half ultimately required open repair for failure of the
endovascular graft. Have the authors learned what patient
factors or situations are more likely to result in endovascular
failure?
4) Finally, and similar to the prior question, has this experience
resulted in a change in how the University of Florida group
approaches the care of patients with aortic pathology associ-
ated with Marfan syndrome?
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Volume 55, Number 5 Waterman et al 1241I would like to thank the authors for providing me with a
manuscript and to the Association for the privilege of discussing
this article.
Dr Alyson Lee Waterman. Thank you, Dr Endean. With
regard to your first question, the 76-year-old gentleman did pres-
ent with an infrarenal abdominal aortic aneurysm. This was his first
vascular presentation. He did have a history of lens subluxation and
came with a self-reported history of Marfan syndrome. Although
he seemed to have the body habitus of Marfan syndrome, enough
for the clinicians include this as part of his medical history, it is very
possible that he did not, in fact, have a diagnosis of Marfan
syndrome. That is one of the difficulties of Marfan syndrome;
much of the diagnosis is based on clinical features alone and not all
patients undergo genetic screening for the fibrillin mutation. It is
possible that some of these patients in this study do not in fact have
that diagnosis.
With regard to your second question, comparing our endo-
vascular outcomes to open outcomes in the same patient popula-
tion is one of the areas that we have thought about looking at in the
p
vuture. There are a lot of open procedures performed by our
ardiothoracic colleagues in the Marfan population, but we have
ot yet looked at those together.
In terms of what factors result in treatment failure, I do not
hink that we can clearly identify from this study, exactly which
actors result in treatment failure. I do think that the Marfan
opulation has a spectrum of disease. Some of these patients seem
o have a more mild form of disease, having one intervention, and
he remainder of their aorta does not degenerate. Some of these
atients, however, even after multiple open and/or endovascular
nterventions, still continue to have aortic degeneration and re-
uire further procedures.
In terms of a change in our management, I think that this
tudy is going to make us look more critically at which patients we
ffer endovascular repair to. I think that there still is a place for
ndovascular repair to be offered, but I think we have to examine
ery closely which patients are offered this therapy, and these
atients all need to be followed very closely for any further inter-
entions they might require.
